Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2007

View Archived Issues

Safety and immunogenicity of new oral vaccine against enterotoxigenic E. coli demonstrated in humans

Novel nanoparticle-based technology ensures effective delivery of therapeutic siRNA in vivo

Dose-escalation trial to establish optimal dose of AL-02

Recent patents disclose novel treatment options for cardiovascular disorders

Recent University of Pittsburgh patent reports novel diagnostic agents for Alzheimer's disease

Recent patents impart new therapeutic agents for cancer

Incyte recaps active quarter

Organon's natural estrogen contraceptive enters phase III trials

Update on Peptech and EvoGenix merger

Phase III Revlimid trial halted based on positive findings

Telomerase activator shows beneficial effects on human aging

Cyto Pulse and KCC develop DNA vaccine for prostate application

Tsumura discontinues development of TU-025 in U.S.

Patient enrollment completed in phase III trial of pirfenidone in IPF patients

Medarex and Organon announce therapeutic antibody collaboration

QuatRx licenses becocalcidiol to CollaGenex

Next-generation nasal spray flu vaccine enters phase I trial

CF-101 enters clinic for third therapeutic indication

Efficacy and MOA of BioLineRx's BL-1020 for schizophrenia sought in clinic

Fast track designation received for romidepsin

Sirion commences phase III evaluation of two of its compounds

Tapestry Pharmaceuticals reports update on next-generation taxane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...